"One of the most challenging aspects of managing a bio/pharma collaboration is navigating your way through the minefield that is taxation. No matter the size of the companies involved, a number of scenarios and issues need some serious TLC, such as: foreign and U.S. partnerships implications; the impact on R&D credit eligibility; Permanent Establishment issues; withholding tax issues; and tax accounting for income and deductions. This session will address the potential taxation trouble areas that are a natural part of any bio/pharma collaboration and assess the best way to ensure that of all the problems a collaboration might have, tax is not one of them."

Objective1:Review the tax issues that bio/pharma companies face.

Objective2:Provide plain English solutions to CEOs and CFOs.

Objective3:Review examples of real-life tax issues and key lessons learned.